Last reviewed · How we verify
Butorphanol Tartrate Injection
At a glance
| Generic name | Butorphanol Tartrate Injection |
|---|---|
| Also known as | the drug of butorphanol tartrate |
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain (PHASE4)
- Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation (NA)
- Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function (NA)
- Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery (NA)
- Intravenous Dexmedetomidine for Cesarean Section (PHASE4)
- Using Preoperative Anxiety Score to Determine the Total Dose of Butorphanol for Sedation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butorphanol Tartrate Injection CI brief — competitive landscape report
- Butorphanol Tartrate Injection updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI